Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:ELUT NASDAQ:PMVP NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$3.95+0.5%$4.46$3.02▼$6.47$21.27M-0.76118,621 shs78,703 shsELUTElutia$1.28-2.3%$2.04$1.28▼$5.12$55.54M0.89160,796 shs410,670 shsPMVPPMV Pharmaceuticals$1.23$1.41$0.81▼$1.84$65.18M1.522.47 million shs1.68 million shsSLGLSol-Gel Technologies$24.63+2.3%$16.04$4.01▼$30.00$67.08M1.2632,768 shs13,244 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+0.51%+1.28%+7.34%-5.95%-39.32%ELUTElutia-2.29%-31.91%-40.74%-28.09%-70.51%PMVPPMV Pharmaceuticals0.00%-15.75%-19.08%+13.89%-18.54%SLGLSol-Gel Technologies+2.26%-11.93%+59.39%+227.46%+275.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$3.95+0.5%$4.46$3.02▼$6.47$21.27M-0.76118,621 shs78,703 shsELUTElutia$1.28-2.3%$2.04$1.28▼$5.12$55.54M0.89160,796 shs410,670 shsPMVPPMV Pharmaceuticals$1.23$1.41$0.81▼$1.84$65.18M1.522.47 million shs1.68 million shsSLGLSol-Gel Technologies$24.63+2.3%$16.04$4.01▼$30.00$67.08M1.2632,768 shs13,244 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+0.51%+1.28%+7.34%-5.95%-39.32%ELUTElutia-2.29%-31.91%-40.74%-28.09%-70.51%PMVPPMV Pharmaceuticals0.00%-15.75%-19.08%+13.89%-18.54%SLGLSol-Gel Technologies+2.26%-11.93%+59.39%+227.46%+275.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.25564.56% UpsideELUTElutia 3.00Buy$7.00446.88% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50347.15% UpsideSLGLSol-Gel Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CING, ELUT, SLGL, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $6.008/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$2.32 per shareN/AELUTElutia$24.38M2.23N/AN/A($1.31) per share-0.98PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ASLGLSol-Gel Technologies$11.54M5.95N/AN/A$10.36 per share2.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)ELUTElutia-$53.95M-$1.06N/AN/AN/A-90.01%N/A-54.08%11/13/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)Latest CING, ELUT, SLGL, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/15/2025Q2 2025SLGLSol-Gel Technologies-$0.67$4.17+$4.84$4.17$2.86 million$17.26 million8/14/2025Q2 2025ELUTElutia-$0.17-$0.26-$0.09-$0.26$6.55 million$6.26 million8/7/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39-$0.41-$0.02-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A1.521.52ELUTElutiaN/A0.590.45PMVPPMV PharmaceuticalsN/A12.5212.52SLGLSol-Gel TechnologiesN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%ELUTElutia74.03%PMVPPMV Pharmaceuticals90.20%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipCINGCingulate4.04%ELUTElutia27.60%PMVPPMV Pharmaceuticals7.57%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate205.41 million5.19 millionNot OptionableELUTElutia18042.40 million30.69 millionNot OptionablePMVPPMV Pharmaceuticals5052.99 million48.98 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableCING, ELUT, SLGL, and PMVP HeadlinesRecent News About These CompaniesSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 36.6% in AugustSeptember 8, 2025 | marketbeat.comSol-Gel Announces Health Canada Approval of EPSOLAY®September 4, 2025 | finance.yahoo.comSol-Gel Technologies announces Health Canada approval of EPSOLAYSeptember 4, 2025 | msn.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 240% return over the last yearSeptember 4, 2025 | finance.yahoo.comSol Gel Technologies trading halted, volatility trading pauseAugust 22, 2025 | msn.comSol-Gel Stock Delivers Over 150% Gain - Can The Upcoming Q4 Clinical Data Readout Sustain The Rally? August 21, 2025 | rttnews.comSol-Gel Technologies Reports Strong Q2 2025 ResultsAugust 20, 2025 | msn.comSol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 15, 2025 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJJuly 25, 2025 | wsj.comSol-Gel Technologies Ltd. (SLGL) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSLGL Sol-Gel Technologies Ltd. - Seeking AlphaJune 26, 2025 | seekingalpha.comSol-Gel Technologies LtdJune 21, 2025 | morningstar.comMSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comQSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comSol-Gel Announces Reverse Share SplitMay 1, 2025 | globenewswire.comSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Costco and Ross: 2 Ways to Play the Consumer DivideBy Chris Markoch | August 24, 2025Williams-Sonoma Q2 Results Prove Its Buy-and-Hold QualityBy Thomas Hughes | August 27, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025CING, ELUT, SLGL, and PMVP Company DescriptionsCingulate NASDAQ:CING$3.95 +0.02 (+0.51%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.96 +0.01 (+0.38%) As of 09/12/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Elutia NASDAQ:ELUT$1.28 -0.03 (-2.29%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 09/12/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.PMV Pharmaceuticals NASDAQ:PMVP$1.23 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.41%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Sol-Gel Technologies NASDAQ:SLGL$24.62 +0.55 (+2.26%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$24.62 0.00 (0.00%) As of 09/12/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
